Compare Stocks → Grab Your Free Bitcoin Today! (From Crypto Swap Profits) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NYSE:BKDNYSEARCA:FBTNASDAQ:TERN Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBKDBrookdale Senior Living$6.62+0.5%$5.89$2.69▼$6.71$1.25B1.311.86 million shs3.04 million shsFBTFirst Trust NYSE Arca Biotechnology Index Fund$153.77-0.6%$151.52$130.27▼$161.41$1.40B0.7929,924 shs19,185 shsTERNTerns Pharmaceuticals$6.56+6.5%$6.64$3.26▼$14.04$398.25M-0.611.17 million shs1.23 million shs20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBKDBrookdale Senior Living+0.30%+1.69%+11.93%+13.66%+128.89%FBTFirst Trust NYSE Arca Biotechnology Index Fund-0.63%-0.18%-0.08%-2.71%+0.50%TERNTerns Pharmaceuticals+6.49%+0.15%-17.90%+1.08%-45.33%Major Elon Musk Crypto Leak Revealed (Ad)Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBKDBrookdale Senior Living2.3148 of 5 stars2.30.00.04.91.11.70.6FBTFirst Trust NYSE Arca Biotechnology Index FundN/AN/AN/AN/AN/AN/AN/AN/ATERNTerns Pharmaceuticals3.8717 of 5 stars3.42.00.04.12.42.50.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBKDBrookdale Senior Living2.50Moderate Buy$7.5013.38% UpsideFBTFirst Trust NYSE Arca Biotechnology Index Fund0.00N/A$194.1026.23% UpsideTERNTerns Pharmaceuticals2.75Moderate Buy$14.94127.71% UpsideCurrent Analyst RatingsLatest RDT, BKD, TERN, and FBT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/27/2024TERNTerns PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$19.00 ➝ $18.003/18/2024TERNTerns PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$17.00 ➝ $15.003/15/2024TERNTerns PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$5.503/15/2024TERNTerns PharmaceuticalsBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$18.00 ➝ $19.001/10/2024TERNTerns PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$8.00 ➝ $5.50(Data available from 3/29/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBKDBrookdale Senior Living$3.02B0.42$0.88 per share7.53$2.15 per share3.08FBTFirst Trust NYSE Arca Biotechnology Index FundN/AN/AN/AN/AN/AN/ATERNTerns Pharmaceuticals$1M424.10N/AN/A$4.13 per share1.59Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBKDBrookdale Senior Living-$189.01M-$0.84N/AN/AN/A-6.27%-44.01%-3.75%5/13/2024 (Estimated)FBTFirst Trust NYSE Arca Biotechnology Index FundN/AN/A17.74∞N/AN/AN/AN/AN/ATERNTerns Pharmaceuticals-$90.21M-$1.27N/AN/AN/AN/A-33.55%-31.90%5/20/2024 (Estimated)Latest RDT, BKD, TERN, and FBT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/14/2024Q4 2023TERNTerns Pharmaceuticals-$0.29-$0.29N/A-$0.29N/AN/A2/20/2024Q4 2023BKDBrookdale Senior Living-$0.19-$0.40-$0.21-$0.40N/A$754.48 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBKDBrookdale Senior LivingN/AN/AN/AN/AN/AFBTFirst Trust NYSE Arca Biotechnology Index FundN/AN/AN/AN/AN/ATERNTerns PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBKDBrookdale Senior Living9.400.800.80FBTFirst Trust NYSE Arca Biotechnology Index FundN/AN/AN/ATERNTerns PharmaceuticalsN/A22.3922.39OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBKDBrookdale Senior LivingN/AFBTFirst Trust NYSE Arca Biotechnology Index FundN/ATERNTerns Pharmaceuticals98.26%Insider OwnershipCompanyInsider OwnershipBKDBrookdale Senior Living1.50%FBTFirst Trust NYSE Arca Biotechnology Index FundN/ATERNTerns Pharmaceuticals17.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBKDBrookdale Senior Living25,200189.34 million186.50 millionOptionableFBTFirst Trust NYSE Arca Biotechnology Index FundN/A9.10 millionN/ANot OptionableTERNTerns Pharmaceuticals6664.65 million53.40 millionNot OptionableRDT, BKD, TERN, and FBT HeadlinesSourceHeadlineThis small-cap stock is expected to take off — if its weight-loss pill trial succeedsmarketwatch.com - March 28 at 3:24 PMTerns Pharmaceuticals (NASDAQ:TERN) Given New $18.00 Price Target at UBS Groupamericanbankingnews.com - March 28 at 3:58 AMUBS Group Lowers Terns Pharmaceuticals (NASDAQ:TERN) Price Target to $18.00marketbeat.com - March 27 at 3:09 PMHere’s Why Ozempic And Mounjaro Rivals Won’t Topple Weight Loss Drugmakers Novo Nordisk And Eli Lilly Anytime Soonmsn.com - March 27 at 9:31 AMWall Street's Favorite Biotech Stocks? 3 Names That Could Make You Filthy Richinvestorplace.com - March 25 at 3:00 PMOptimistic Buy Rating for Terns Pharmaceuticals Based on Strong Clinical Pipeline and Financial Stabilitymarkets.businessinsider.com - March 21 at 6:49 AMTerns Pharmaceuticals (NASDAQ:TERN) Given New $15.00 Price Target at JMP Securitiesamericanbankingnews.com - March 19 at 4:54 AMBMO Capital Markets Increases Terns Pharmaceuticals (NASDAQ:TERN) Price Target to $19.00americanbankingnews.com - March 19 at 2:48 AMTerns Pharmaceuticals' (TERN) "Neutral" Rating Reiterated at HC Wainwrightamericanbankingnews.com - March 19 at 2:48 AMHC Wainwright Reaffirms "Neutral" Rating for Terns Pharmaceuticals (NASDAQ:TERN)marketbeat.com - March 18 at 6:33 PMTerns Pharmaceuticals (NASDAQ:TERN) PT Raised to $19.00marketbeat.com - March 18 at 6:33 PMTerns Pharmaceuticals (NASDAQ:TERN) PT Lowered to $15.00marketbeat.com - March 18 at 5:31 PMTERN Apr 2024 15.000 callfinance.yahoo.com - March 16 at 1:45 PMTerns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updatesglobenewswire.com - March 14 at 4:05 PMTerns Pharmaceuticals, Inc.: Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemiafinanznachrichten.de - March 12 at 4:18 AMTerns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemiaglobenewswire.com - March 11 at 4:05 PMTerns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)globenewswire.com - March 7 at 4:05 PMFmr LLC Sells 1,932,296 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN)marketbeat.com - March 4 at 5:19 AMAcuta Capital Partners LLC Lowers Position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)marketbeat.com - March 3 at 12:18 PMTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Holdings Lifted by Braidwell LPmarketbeat.com - March 1 at 10:18 AMBarclays PLC Decreases Stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)marketbeat.com - February 29 at 4:16 AMTerns Pharmaceuticals to Participate in Upcoming March Investor Conferencesglobenewswire.com - February 27 at 4:05 PMTerns Pharmaceuticals, Inc.: Terns Pharmaceuticals Reports Inducement Grants to New Chief Executive Officer Under Nasdaq Listing Rule 5635(C)(4)finanznachrichten.de - February 9 at 9:57 AMTerns Pharmaceuticals, Inc.: Terns Pharmaceuticals Appoints Amy Burroughs as Chief Executive Officerfinanznachrichten.de - February 7 at 5:40 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesThe Ozempic Diet Trend is Lifting These 2 Carnivore StocksMarch 4, 2024 6:28 AMView The Ozempic Diet Trend is Lifting These 2 Carnivore StocksSea Limited: The One-Stop Digital Consumer Platform of AsiaMarch 13, 2024 6:10 AMView Sea Limited: The One-Stop Digital Consumer Platform of AsiaOkta Raises EPS Forecasts Despite High Profile Security BreachesMarch 7, 2024 6:23 AMView Okta Raises EPS Forecasts Despite High Profile Security BreachesPDD Holdings Stock Can Have Another Double-Digit Rally This WeekMarch 20, 2024 8:00 AMView PDD Holdings Stock Can Have Another Double-Digit Rally This WeekCan WeightWatchers Regain its Mojo after Oprah Steps Down? March 13, 2024 7:04 AMView Can WeightWatchers Regain its Mojo after Oprah Steps Down? All Headlines Company DescriptionsBrookdale Senior LivingNYSE:BKDBrookdale Senior Living Inc. owns, manages, and operates senior living communities in the United States. It operates in three segments: Independent Living, Assisted Living and Memory Care, and Continuing Care Retirement Communities (CCRCs). The Independent Living segment owns or leases communities comprising independent and assisted living units in a single community that are primarily designed for middle to upper income seniors. The Assisted Living and Memory Care segment owns or leases communities consisting of freestanding, multi-story communities and freestanding, single-story communities, which offer housing and 24-hour assistance with activities of daily living for the Company's residents. This segment also operates memory care communities for residents with Alzheimer's and other dementias. The CCRCs segment owns or leases communities that provides various living arrangements, such as independent and assisted living, memory care, and skilled nursing; and services to accommodate various levels of physical ability and healthcare needs. It also manages communities on behalf of others. Brookdale Senior Living Inc. was incorporated in 2005 and is headquartered in Brentwood, Tennessee.First Trust NYSE Arca Biotechnology Index FundNYSEARCA:FBTThe First Trust NYSE Arca Biotechnology Index Fund (FBT) is an exchange-traded fund that is based on the NYSE Arca Biotechnology index. The fund tracks an equal-weighted index of US biotechnology stocks. FBT was launched on Jun 19, 2006 and is managed by First Trust.Terns PharmaceuticalsNASDAQ:TERNTerns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.